IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Genius — OpenServe

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

OpenServe Drive OpenServe Inbox OpenServe Write OpenServe Studio OpenServe Projects OpenServe Focus OpenServe Mindmaps Teams OpenServe CRM Site Builder Whiteboard

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Popular
Elections

Genius — OpenServe

Kate Returns to Premiere After Cancer Treatment — Sep 22, 2026The Prince and Princess of Wales walked the London red carpet for Tom Cruise’s Digger premiere, with Kate in a jewel-toned Jenny Packham gown and wearing the Queen Mother’s Amethyst Sautoir Necklace along with Princess Diana’s Collingwood Pearl Drop Earrings. They also attended a charity screening in Leicester Square related to the Film and TV Charity, continuing their high-profile appearances around the premiere.

0

FedEx Shift Ends With a Baby Delivery — Jan 30, 2026What began as an ordinary workday inside an Iowa FedEx facility turned into a moment Amethyst Blumberg will never forget. Blumberg’s shift in Grimes was winding down early Monday morning when she suddenly felt something…

0

Crystalys Therapeutics raises $130M Series B — Jul 22, 2026Crystalys Therapeutics has raised a $130 million Series B led by Frazier Life Sciences with participation from multiple investors to fund late-stage global trials and commercialization plans for dotinurad, its URAT1 inhibitor for gout. The financing backs the RUBY, TOPAZ, and AMETHYST studies and aims to accelerate regulatory milestones and commercial readiness across the U.S. and Europe as the company positions dotinurad as a best-in-class option between first-line therapies and last-line treatments.

0